Withdrawal phenomena and dependence syndrome after the consumption of "spice gold".
Ulrich S Zimmermann, Patricia R Winkelmann, Max Pilhatsch, Josef A Nees, Rainer Spanagel, Katja Schulz
Deutsches Arzteblatt international July 3, 2009 DOI: 10.3238/arztebl.2009.0464 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A 20-year-old male daily "Spice Gold" user |
| Duration | 8 months of daily use; withdrawal symptoms observed on hospital days 4-7 |
| Topics | Addiction |
| Keywords | Humans Substance-related disorders Substance withdrawal syndrome Cannabinoids Male Young adult Drug abuse Designer drugs Addictive behavior Drug-withdrawal therapy Pathogenesis of addiction |
| Key findings | The authors interpret the patient's symptoms as a dependence syndrome meeting ICD-10 and DSM-IV criteria, with a physical withdrawal syndrome closely resembling cannabis dependence. They postulate the syndrome was caused by undeclared synthetic cannabinomimetics such as JWH-018 and CP 47497 in "Spice Gold," combined with the patient's very large daily consumption. |
Abstract
Background: "Spice" and other herbal blends were marketed in Germany until January 2009 as substances purportedly exerting similar effects to cannabis, yet containing no cannabinoids. These products were recently forbidden in Germany under the provisions of the German Narcotics Law after they were found to contain undeclared, synthetic cannabinomimetic substances. The authors describe physical withdrawal phenomena and a dependence syndrome that developed after the consumption of "Spice." Case presentation and course: A 20-year old patient reported that he had smoked "Spice Gold" daily for 8 months. He developed tolerance and rapidly increased the dose to 3 g per day. He felt a continuous desire for the drug and kept on using it despite the development of persistent cognitive impairment. His substance use led him to neglect his duties in his professional training position. Urinary drug screens were negative on admission to the hospital, as they were again on discharge. On hospital days 4-7, he developed inner unrest, drug craving, nocturnal nightmares, profuse sweating, nausea, tremor, and headache. His blood pressure was elevated for two days, with a maximal value of 180/90 mm Hg accompanied by a heart rate of 125/min. The patient stated that he had experienced a similar syndrome a few weeks earlier during a phase of abstinence owing to a short supply, and that it had quickly subsided after he had started consuming "Spice" once again.
Conclusions: The authors interpret the symptoms and signs described above as a dependence syndrome corresponding to the ICD-10 and DSM-IV criteria for this entity. The physical withdrawal syndrome closely resembles that seen in cannabis dependence. The authors postulate that the syndrome in the patient described was due to an admixture of synthetic cannabinomimetics such as JWH-018 and CP 47497 in "Spice Gold," in combination with the patient's daily consumption in very large amounts.
Comparable studies
Other case reports and case series on addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ecstasy (MDMA) dependence Individuals meeting criteria for MDMA dependence | 1999 | Case series | n = 3 |
| Potential Human Neurotoxicity of MDMA (‘Ecstasy’): Subjective Self-Reports, Evidence from an Italian Drug Addiction Centre and Clinical Case Studies Polydrug consumers attending a Public Health Addiction Treatment Unit in Italy | 2000 | Review and clinical case series | |
| A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. 31-year-old male military veteran with moderate alcohol use disorder | 2018 | Case study | n = 1 |
| LSD Overdoses: Three Case Reports Three individuals who experienced accidental LSD overdose | 2020 | Case series | n = 3 |
| Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report. 37-year-old female with severe opioid use disorder | 2016 | Case study | n = 1 |
Citations in the library
Cited by 45
- Beyond THC: The New Generation of Cannabinoid Designer Drugs Frontiers in Behavioral Neuroscience 2011
- Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. Journal of Medical Toxicology March 1, 2012
- Novel psychoactive substances of interest for psychiatry World Psychiatry February 1, 2016
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. Forensic Science International March 20, 2011
and 40 more in the library